Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF -1.97%69 Net Cash per Share is $1.00 as of Mar. 2026, which is 84% below its 10-year median of 6.42. GuruFocus rates PROF with a GF Score™ of 69/100 and a GF Value™ of $14.52 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 303 Medical Devices & Instruments companies, Profound Medical ranks better than 52.15% on this metric.
The historical rank and industry rank for Profound Medical's Net Cash per Share or its related term are showing as below:
PROF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.07 Med: 6.42 Max: 119.09
Current: 7.13
During the past 12 years, the highest Price-to-Net-Cash Ratio of Profound Medical was 119.09. The lowest was 2.07. And the median was 6.42.
PROF's Price-to-Net-Cash is ranked better than 52.15% of 303
companies
in the Medical Devices & Instruments industry
Industry Median: 7.76
vs PROF: 7.13
Profound Medical (NAS:PROF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Profound Medical Net Cash per Share Related Terms
Profound Medical Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Profound Medical's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROF vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, Profound Medical's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Profound Medical's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Profound Medical's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a Net Cash per Share of $1.00 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Profound Medical and its competitors. This is 84% below median its historical median of 6.42. Over the past decade, Profound Medical's Net Cash per Share has ranged from 2.07 to 119.09. According to the industry distribution chart, Profound Medical ranks #145 out of 303 companies in the Medical Devices & Instruments industry, placing it in the top 47.9%.
Is Profound Medical's Net Cash per Share too high?
Profound Medical's current Net Cash per Share of $1.00 is 84% below median its 10-year median of 6.42. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 119.09. The Medical Devices & Instruments industry median Net Cash per Share is 7.76. Profound Medical's value of $1.00 is 87.1% below this industry median. Based on the distribution chart, Profound Medical ranks #145 out of 303 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #145 out of 303 companies for Net Cash per Share. This puts Profound Medical in the upper half of its industry. The industry median Net Cash per Share is 7.76. Profound Medical's value of $1.00 is 87.1% below this benchmark. Historically, Profound Medical's own Net Cash per Share has ranged from 2.07 to 119.09 over the past decade. While the company's 10-year median is 6.42 vs. the industry median of 7.76, Profound Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 7.76, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Net Cash per Share of $1.00 is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 7.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Net Cash per Share is $1.00, which is 84% below median its own 10-year median of 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.52, compared to a current price of $6.92 — trading 52.3% below its estimated fair value. The current Net Cash per Share is $1.00, which is 84% below median its 10-year median of 6.42 and 87.1% below the Medical Devices & Instruments industry median of 7.76. Profound Medical's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Profound Medical (PROF), the current Net Cash per Share is $1.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $6.92 is trading 52.3% below its estimated GF Value™ of $14.52.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Net Cash per Share: $1.00 (84% below median its 10-year median of 6.42)
GF Value™: $14.52 vs. price of $6.92 (52.3% below fair value)
Industry Position: 87.1% below the Medical Devices & Instruments median (#145 of 303)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
69GF Score
Get the complete analysis for PROF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
